Ron Wyden actually said...
As chairman of the Pricing, Reimbursement, and Access Steering Committee for Lilly USA and as the relevant profit and loss business unit leader for the biomedicines business unit for the United States, I approved pricing recommendations for this medicine.
01/08/2018